Project Grant R01CA298159
Award Date 8/6/25
Completion Date 7/31/29
Dollars Obligated $2.8M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $686,979 to The Regents of the University of California, San Francisco (UCSF) to develop an integrated metabolic therapy and imaging strategy for diffuse midline gliomas (DMGs), a type of malignant brain tumor in children. The key objectives are to: Investigate how the H3K27M mutation that drives DMG tumorigenesis affects tumor cell metabolism and the tumor microenvironment. Determine...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $655,306 to The Regents of the University of California, San Francisco (UCSF) to develop and evaluate a therapeutic strategy that combines a brain-penetrant glyoxalase 1 (GLO1) inhibitor with radiation for the treatment of isocitrate dehydrogenase-mutant (IDHm) gliomas, one of the deadliest forms of brain cancer. The project aims to mechanistically validate reactive metabolite...
- This $3,155,815 Project Grant award from the National Cancer Institute (NCI), under the CFDA 93.394 Cancer Detection and Diagnosis Research program, supports research to develop advanced magnetic resonance imaging techniques for non-invasive measurement of glutamate metabolism in glioblastoma brain tumors. The primary awardee is Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, which will leverage its expertise in medical research, imaging technologies, and...
- This $997,410 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop non-invasive MRI-based techniques to detect and differentiate between the invasive neuronal (NEU) and glycolytic/plurimetabolic (GPM) subtypes of high-grade glioma brain tumors. The project leverages recent discoveries about these tumor subtypes' distinct microstructural, metabolic, and synapse profiles to enable more comprehensive tumor...
- This $640,135 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a new generation of potent menin inhibitors that can overcome resistance observed in current menin inhibitor treatments for acute myeloid leukemia (AML) patients. The award recipient, the Regents of the University of Michigan, will leverage its expertise in medicinal chemistry and cancer biology to design and test these next-generation menin...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Rochester provides $639,098 to develop an innovative treatment for metastatic pancreatic cancer. The research aims to overcome both intrinsic and extrinsic barriers to treatment efficacy, specifically by targeting the tumor microenvironment through a combination of local radiotherapy and intratumoral immunotherapy using a novel mRNA-based nanoparticle delivery system. The...
- This federal Project Grant award of $128,199 from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research by the Regents of the University of Michigan to investigate the role of the lipid kinase PIKFYVE in regulating metabolic homeostasis in pancreatic ductal adenocarcinoma (PDAC). The research aims to 1) dissect PIKFYVE's function in PDAC metabolism, and 2) determine the mechanism and efficacy of combining PIKFYVE inhibition with KRAS-MAPK inhibition...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $544,478 to The University of Texas Southwestern Medical Center to conduct research on "Decoding the Metabolic Routes of Purine Nucleotides in Cancer". The overarching goal is to expand the mechanistic understanding of purine synthesis pathways in tumors and identify new strategies to target purine supply mechanisms for effective cancer treatment. Key research aims include:...
- This Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $210,600 to the Regents of the University of Michigan to analytically validate and evaluate an H3K27M circulating tumor DNA (ctDNA) assay for monitoring diffuse midline glioma (DMG) patients. The project aims to establish the analytical performance characteristics of this high-sensitivity ctDNA assay as a CLIA-compliant laboratory developed test (LDT) and then...
- The University of Michigan was awarded a $2,284,054 Project Grant by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research (CFDA 93.394) federal grant program. The 4-year grant, which began on September 1, 2025, will support research to transform molecular cancer screening through the development of stimulated Raman histology and deep neural networks. The project aims to improve access to molecular cancer testing by creating innovative diagnostic tools and methods...